News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Libby Black, PharmD

Articles by Libby Black, PharmD

Finasteride Versus Dutasteride: A Real-world Economic Evaluation

ByThomas C. Fenter, MD,M. Chris Runken, PharmD,Libby Black, PharmD,Michael Eaddy, PharmD, PhD

February 1st 2007

Differences in Alpha Blocker Usage Among Enlarged Prostate Patients Receiving Combination Therapy with 5 ARIs

ByMichael Naslund, MD, MBA,Libby Black, PharmD,Michael Eaddy, PharmD, PhD,LaKeasha R. Batiste, MS

February 1st 2007

Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate

ByMichael James Naslund, MD, MBA,Muta M. Issa, MD, MBA,Amy L. Grogg, PharmD,Michael T. Eaddy, PharmD, PhD,Libby Black, PharmD

March 1st 2006

An Examination of Treatment Patterns and Costs of Care Among Patients With Benign Prostatic Hyperplasia

ByLibby Black, PharmD,Michael James Naslund, MD, MBA,Thomas D. Gilbert, Jr, MS,E. Anne Davis, PharmD, MS,Daniel A. Ollendorf, MPH

March 1st 2006

An Assessment of the Diagnosed Prevalence of Diseases in Men 50 Years of Age or Older

ByMuta M. Issa, MD, MBA,Thomas C. Fenter, MD,Libby Black, PharmD,Amy L. Grogg, PharmD,Eric J. Kruep, PharmD, MS

March 1st 2006

The Cost of Treating the 10 Most Prevalent Diseases in Men 50 Years of Age and Older

ByThomas C. Fenter, MD,Michael James Naslund, MD, MBA,Manan B. Shah, PharmD, PhD,Michael T. Eaddy, PharmD, PhD,Libby Black, PharmD

March 1st 2006

The Hidden Condition: Status, Challenges, and Opportunities in the Management of Enlarged Prostate for Managed Care

ByMichael James Naslund, MD, MBA,Evelyn Chiao, PharmD,Libby Black, PharmD,Michael T. Eaddy, PharmD, PhD

March 1st 2006

Latest Updated Articles

Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate
March 1st 2006
An Examination of Treatment Patterns and Costs of Care Among Patients With Benign Prostatic Hyperplasia
March 1st 2006
An Assessment of the Diagnosed Prevalence of Diseases in Men 50 Years of Age or Older
March 1st 2006
The Cost of Treating the 10 Most Prevalent Diseases in Men 50 Years of Age and Older
March 1st 2006
The Hidden Condition: Status, Challenges, and Opportunities in the Management of Enlarged Prostate for Managed Care
March 1st 2006
Finasteride Versus Dutasteride: A Real-world Economic Evaluation
February 1st 2007

Trending on AJMC

Counseling Vitiligo Patients on Time to Repigmentation

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

5 August FDA Approvals Marked by Novelty, Pushback

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD